Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01275209 · ClinicalTrials.gov registry record · Phase 1
Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Lymphoma
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT01275209 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1 participants.
The verdict
NCT01275209, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This study will assess the safety and efficacy of HCD122 (Lucatumumab) when combined with bendamustine in patients with follicular lymphoma.
Interventions
- DRUG HCD122
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2011-02 |
| Est. Completion | 2012-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01275209
The ClinicalTrials.gov registry entry for NCT01275209 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HCD122 is the first listed.
NCT01275209 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01275209 about?
NCT01275209 is a clinical study titled "Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Lymphoma". This study will assess the safety and efficacy of HCD122 (Lucatumumab) when combined with bendamustine in patients with follicular lymphoma.
What is the current status of trial NCT01275209?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2011-02. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01275209?
The interventions under investigation include: HCD122 (DRUG).
Who is sponsoring clinical trial NCT01275209?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.